Effect of long-term supplementation of low molecular weight chitosan oligosaccharide (GO2KA1) on fasting blood glucose and HbA1c in db/db mice model and elucidation of mechanism of action

BMC Complementary and Alternative Medicine

Young-In Kwon²  Emmanouil Apostolidis¹  Young-Cheul Kim³  Sung-Chul Kim⁴  Kyoung-Soo Ha²  Sung-Hoon Jo²  Jong-Gwan Kim⁴ 

[1] Department of Chemistry and Food Science, Framingham State University, Framingham, MA 01701, USA;Department of Food and Nutrition, Hannam University, Daejeon 305-811, Korea;Department of Nutrition, University of Massachusetts, Amherst, MA 01003, USA;Kunpoong Bio Co., Ltd., Gumnung-ri, 407–11, Hallim-eup, Jeju Special Self Governing Province, Jeju 695-923, Korea

关键词: GO2KA1;    Low molecular chitosan oligosacharide;    Glucosidase inhibitors;    Blood glucose;    Pre-diabetes;    Type 2 diabetes;   

Others  :  1087152
DOI  :  10.1186/1472-6882-14-272

 received in 2013-10-16, accepted in 2014-07-21,  发布年份 2014

【 摘 要 】

Background

Type 2 diabetes is a serious problem for developed countries. Prevention of prediabetes progression to type 2 diabetes with the use of natural products appears to a cost-effective solution. Previously we showed that enzymatically digested low molecular weight chitosan-oligosaccharide with molecular weight (MW) below 1,000 Da (GO2KA1) has potential for hyperglycemia management.

Methods

In this study we evaluated the effect of long-term supplementation of GO2KA1 on hyperglycemia using a db/db mice model. Additionally, we evaluated the effect of GO2KA1 on sucrase and glucoamylase activities and expression, using the same db/db mice model.

Results

After 42 days we observed that GO2KA1 supplementation reduced both the blood glucose level and HbA1c in a similar manner with a known anti-diabetic drug, acarbose. When the sucrase and glucoamylase activities of GO2KA1 and control mice were evaluated using enzymatic assay, we observed that GO2KA1 significantly inhibited sucrase in all 3 parts of the intestine, while glucoamylase activity was significantly reduced only in the middle and lower part. When the sucrase-isomaltase (SI) complex expression on mRNA level was evaluated, we observed that GO2KA1 had minimal inhibitory effect on the upper part, more pronounced inhibitory effect on the middle part, while the highest inhibition was observed on the lower part. Our findings suggest that long-term GO2KA1 supplementation in db/db mice results to significant blood glucose and HbA1c reduction, to levels similar with those of acarbose. Furthermore, our findings confirm previous in vitro observations that GO2KA1 has inhibitory effect on carbohydrate hydrolysis enzymes, namely sucrase, maltase and SI complex.

Conclusions

Results from this study provide a strong rationale for the use of GO2KA1 for type 2 diabetes prevention, via inhibition of carbohydrate hydrolysis enzymes. Based on the findings of this animal trial, clinical trials will be designed and pursued.

【 授权许可】

   
2014 Kim et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

【 参考文献 】

• [1]Center for Disease Control 2011. http://www.cdc.gov/diabetes/pubs/pdf/ndfs_2011.pdf webcite
• [2]James RG: Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 2002, 25:s5-s20.
• [3]World Health Organization http://www.who.int/mediacentre/factsheets/fs312/en/index.html webcite
• [4]American Diabetes Association http://www.diabetes.org/diabetes-basics/diagnosis/?loc=DropDownDB-diagnosis webcite
• [5]Hanefeld M: Cardiovascular benefits and safety profile of acarbose therapy in prediabetes and established type 2 diabetes. Cardiovasc Diabetol 2007, 6:20.
• [6]Jenkins DJ, Taylor RH, Goff DV, Fielden H, Misiewicz JJ, Sarson DL, Bloom SR, Alberti KG: Scope and specificity of acarbose in slowing carbohydrate absorption in man. Diabetes 1981, 30:951-954.
• [7]Haffner SM: The importance of hyperglycemia in the nonfasting state to the development of cardiovascular disease. Endocr Rev 1998, 19:583-592.
• [8]Di Carli MF, Janisse J, Grunberger G, Ager J: Role of chronic hyperglycemia in the pathogenesis of coronary microvascular dysfunction in diabetes. J Am Coll Cardiol 2003, 41:1387-1393.
• [9]Puls W, Keup U, Krause HP, Thomas G, Hoffmeister F: Glucosidase inhibition. A new approach to the treatment of diabetes, obesity, and hyperlipoproteinaemia. Naturwissenschaften 1977, 64:536-537.
• [10]Martin A, Montgomery P: Acarbose: an alpha-glucosidase inhibitor. Am J Health-Syst Pharm 1996, 53:2277-2290.
• [11]Andlauer W, Furst P: Special characteristics of non-nutrient food constituents of plants–phytochemicals. Introductory lecture. Int J Vitam Nutr Res 2003, 73:55-62.
• [12]Apostolidis E, Kwon YI, Shetty K: Potential of cranberry-based herbal synergies for diabetes and hypertension management. Asia Pac J Clin Nutr 2006, 15:433-441.
• [13]Kwon YI, Vattem DA, Shetty K: Evaluation of clonal herbs of Lamiaceae species for management of diabetes and hypertension. Asia Pac J Clin Nutr 2006, 15:107-118.
• [14]Kwon YI, Apostolidis E, Kim YC, Shetty K: Health benefits of traditional corn, beans, and pumpkin: in vitro studies for hyperglycemia and hypertension management. J Med Food 2007, 10:266-275.
• [15]Kim MS, You HJ, You MK, Kim NS, Shim BS, Kim HM: Inhibitory effect of water-soluble chitosan on TNF-alpha and IL-8 secretion from HMC-1 cells. Immunopharmacol Immunotoxicol 2004, 26:401-409.
• [16]Theoharides TC, Cochrane DE: Critical role of mast cells in inflammatory diseases and the effect of acute stress. J Neuroimmunol 2004, 146:1-12.
• [17]Nishimoto N, Kishimoto T: Inhibition of IL-6 for the treatment of inflammatory diseases. Curr Opin Pharmacol 2004, 4:386-391.
• [18]Huang R, Mendis E, Kim SK: Improvement of ACE inhibitory activity of chitooligosaccharides (COS) by carboxyl modification. Bioorg Med Chem 2005, 13:3649-3655.
• [19]Kondo Y, Nakatani A, Hayashi K, Ito M: Low molecular weight chitosan prevents the progression of low dose streptozotocin-induced slowly progressive diabetes mellitus in mice. Biol Pharm Bull 2000, 23:1458-1464.
• [20]Kim YCK SH, Yoon SP, Kim JW: Reducing effect of chitosan oligosaccharide on postprandial blood glucose level in Koreans. J Chitin and Chitosan 2009, 14:107-111.
• [21]Jo SH, Ha KS, Moon KS, Kim JG, Oh CG, Kim YC, Apostolidis E, Kwon YI: Molecular weight dependent glucose lowering effect of low molecular weight chitosan oligosaccharide (GO2KA1) on postprandial blood glucose level in SD rats model. Int J Mol Sci 2013, 14:14214-14224.
• [22]Dahlqvist A: Method for assay of intestinal disaccharidases. Anal Biochem 1964, 7:18-25.
• [23]Krentz A, Bailey C: Oral antidiabetic agents. Drugs 2005, 65:385-411.
• [24]Dehghan-Kooshkghazi M, Mathers JC: Starch digestion, largebowel fermentation and intestinal mucosal cell proliferation in rats treated with the a-glucosidase inhibitor acarbose. Br J Nutr 2004, 91:357-365.
• [25]Kim GN, Kwon YI, Jang HD: Mulberry leaf extract reduces postprandial hyperglycemia with few side effects by inhibiting a-glucosidase in normal rats. J Med Food 2011, 14:712-717.